| Evaluation and prognostic significance of circulating tumor cells in patients with non–small-cell lung cancer MG Krebs, R Sloane, L Priest, L Lancashire, JM Hou, A Greystoke, ... Journal of clinical oncology 29 (12), 1556-1563, 2011 | 1056 | 2011 |
| Analysis of circulating tumor cells in patients with non-small cell lung cancer using epithelial marker-dependent and-independent approaches MG Krebs, JM Hou, R Sloane, L Lancashire, L Priest, D Nonaka, TH Ward, ... Journal of thoracic oncology 7 (2), 306-315, 2012 | 546 | 2012 |
| Circulating tumor cells as a window on metastasis biology in lung cancer JM Hou, M Krebs, T Ward, R Sloane, L Priest, A Hughes, G Clack, ... The American journal of pathology 178 (3), 989-996, 2011 | 522 | 2011 |
| Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230 R Eastell, JE Adams, RE Coleman, A Howell, RA Hannon, J Cuzick, ... Journal of Clinical Oncology 26 (7), 1051-1057, 2008 | 471 | 2008 |
| Effect of an aromatase inhibitor on BMD and bone turnover markers: 2‐year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230) R Eastell, RA Hannon, J Cuzick, M Dowsett, G Clack, JE Adams Journal of Bone and Mineral Research 21 (8), 1215-1223, 2006 | 372 | 2006 |
| A pilot study to explore circulating tumour cells in pancreatic cancer as a novel biomarker L Khoja, A Backen, R Sloane, L Menasce, D Ryder, M Krebs, R Board, ... British journal of cancer 106 (3), 508-516, 2012 | 303 | 2012 |
| Clinical development of new drug–radiotherapy combinations RA Sharma, R Plummer, JK Stock, TA Greenhalgh, O Ataman, S Kelly, ... Nature reviews Clinical oncology 13 (10), 627-642, 2016 | 290 | 2016 |
| Prevention of aromatase inhibitor–induced bone loss using risedronate: the SABRE trial C Van Poznak, RA Hannon, JR Mackey, M Campone, JP Apffelstaedt, ... Journal of clinical oncology 28 (6), 967-975, 2010 | 267 | 2010 |
| Biomarker utility of circulating tumor cells in metastatic cutaneous melanoma L Khoja, P Lorigan, C Zhou, M Lancashire, J Booth, J Cummings, ... Journal of Investigative Dermatology 133 (6), 1582-1590, 2013 | 158 | 2013 |
| Effects of the Src kinase inhibitor saracatinib (AZD0530) on bone turnover in healthy men: a randomized, double‐blind, placebo‐controlled, multiple‐ascending‐dose phase I trial RA Hannon, G Clack, M Rimmer, A Swaisland, JA Lockton, RD Finkelman, ... Journal of Bone and Mineral Research 25 (3), 463-471, 2010 | 139 | 2010 |
| Circulating melanoma cells and survival in metastatic melanoma C Rao, T Bui, M Connelly, G Doyle, I Karydis, MR Middleton, G Clack, ... International journal of oncology 38 (3), 755-760, 2011 | 131 | 2011 |
| Effects of third generation aromatase inhibitors on bone health and other safety parameters: results of an open, randomised, multi-centre study of letrozole, exemestane and … EV McCloskey, RA Hannon, G Lakner, WD Fraser, G Clack, A Miyamoto, ... European Journal of Cancer 43 (17), 2523-2531, 2007 | 111 | 2007 |
| Long-term effects of anastrozole on bone mineral density: 7-year results from the ATAC trial R Eastell, J Adams, G Clack, A Howell, J Cuzick, J Mackey, ... Annals of Oncology 22 (4), 857-862, 2011 | 104 | 2011 |
| Prevalence and heterogeneity of circulating tumour cells in metastatic cutaneous melanoma L Khoja, P Shenjere, C Hodgson, J Hodgetts, G Clack, A Hughes, ... Melanoma research 24 (1), 40-46, 2014 | 90 | 2014 |
| The ATAC (‘Arimidex’, Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: first results of the endometrial sub-protocol following 2 years of treatment S Duffy, TL Jackson, M Lansdown, K Philips, M Wells, S Pollard, G Clack, ... Human Reproduction 21 (2), 545-553, 2006 | 83 | 2006 |
| PATRIOT: A phase I study to assess the tolerability, safety and biological effects of a specific ataxia telangiectasia and Rad3-related (ATR) inhibitor (AZD6738) as a single … MT Dillon, Z Boylan, D Smith, J Guevara, K Mohammed, C Peckitt, ... Clinical and Translational Radiation Oncology 12, 16-20, 2018 | 79 | 2018 |
| A prototypical process for creating evidentiary standards for biomarkers and diagnostics CA Altar, D Amakye, D Bounos, J Bloom, G Clack, R Dean, ... Clinical Pharmacology & Therapeutics 83 (2), 368-371, 2008 | 68 | 2008 |
| Ceralasertib (AZD6738), an oral ATR kinase inhibitor, in combination with carboplatin in patients with advanced solid tumors: a phase I study TA Yap, MG Krebs, S Postel-Vinay, A El-Khouiery, JC Soria, J Lopez, ... Clinical Cancer Research 27 (19), 5213-5224, 2021 | 65 | 2021 |
| Analytical validation of BRAF mutation testing from circulating free DNA using the amplification refractory mutation testing system KL Aung, E Donald, G Ellison, S Bujac, L Fletcher, M Cantarini, G Brady, ... The Journal of Molecular Diagnostics 16 (3), 343-349, 2014 | 60 | 2014 |
| Current status and future potential of somatic mutation testing from circulating free DNA in patients with solid tumours KL Aung, RE Board, G Ellison, E Donald, T Ward, G Clack, M Ranson, ... The HUGO journal 4, 11-21, 2010 | 59 | 2010 |
John MackeyProfessor of Oncology, University of Alberta在 ualberta.ca 的电子邮件经过验证
